
Updates in chronic graft-versus-host disease
Dec 10, 2021 · Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations of chronic GVHD are heterogeneous and pleomorphic, …
Classification systems for chronic graft-versus-host disease
Chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Clinically, chronic GVHD is a pleiotropic, multiorgan syndrome involving tissue inflammation and fibrosis that …
Graft-versus-host disease - Wikipedia
Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD is commonly associated with bone marrow transplants and stem cell transplants. White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self).
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus …
Jul 14, 2021 · In retrospective surveys, ruxolitinib, a Janus kinase (JAK1–JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.
Chronic GvHD NIH Consensus Project Biology Task Force: evolving …
Aug 25, 2023 · Chronic graft-versus-host disease (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of nonrelapse mortality and significant morbidity. Tremendous progress has been achieved in both the understanding of pathophysiology and the development of new therapies for cGvHD.
FDA approves treatment for chronic graft versus host disease
cGVHD is a life-threatening condition that can occur in patients after they receive a stem cell transplant from blood or bone marrow, called hematopoietic stem cell transplantation (HSCT), to treat...
Treatment of chronic graft-versus-host disease - UpToDate
Sep 25, 2024 · Graft-versus-host disease (GVHD) can develop after allogeneic hematopoietic cell transplant (HCT) when immune cells from a non-identical donor (the graft) initiate an immune reaction against a transplant recipient (the host).
How I treat refractory chronic graft-versus-host disease
Mar 14, 2019 · Approximately 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD).
MEASURING THERAPEUTIC RESPONSE IN CHRONIC GRAFT …
Dec 15, 2000 · In 2005, the NIH Chronic GVHD Consensus Response Criteria Working Group recommended several measures to document serial evaluations of chronic GVHD organ involvement. Provisional definitions of complete response, partial response, and progression were proposed for each organ and for overall outcome.
Epidemiology and Treatment of Chronic Graft-versus-Host Disease …
Oct 22, 2020 · Chronic graft-versus-host disease (cGVHD) is a common complication of hematopoietic cell transplantation. cGVHD is an area of unmet need, as shown by treatment cycling and healthcare cost and resource utilization (HCRU). This study quantifies US cGVHD prevalence, treatment patterns, and HCRU.